Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models

Experimental Neurology

Volumn 270, Issue , 2015, Pages 41-54

  Plomp, Jaap J ^a   Morsch, Marco ^b   Phillips, William D ^c   Verschuuren, Jan J G M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MACQUARIE UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Acetylcholine receptor; Compound muscle action potential; Electromyography; Electrophysiology; Endplate; Mouse models; Muscle specific kinase; Myasthenia gravis; Neuromuscular junction; Synapse

Indexed keywords

AMIFAMPRIDINE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; ECULIZUMAB; NEOSTIGMINE; RITUXIMAB; SALBUTAMOL;

DRUG EFFECT; ELECTROMYOGRAPHY; EX VIVO STUDY; FLACCID PARALYSIS; HUMAN; MICROELECTRODE; MINIATURE ENDPLATE POTENTIAL; MUSCLE ACTION POTENTIAL; MUSCLE BIOPSY; MUSCLE CONTRACTION; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PATCH CLAMP TECHNIQUE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYNAPTIC TRANSMISSION; ANATOMY AND HISTOLOGY; ANIMAL; DISEASE MODEL; ELECTROPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGY; HUMANS; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; SYNAPTIC TRANSMISSION;

EID: 84939436189     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.01.007     Document Type: Review

References (144)

1. Albuquerque E.X., Rash J.E., Mayer R.F., Satterfield J.R. An electrophysiological and morphological study of the neuromuscular junction in patients with myasthenia gravis. Exp. Neurol. 1976, 51:536-563.
2. Angaut-Petit D., Molgo J., Connold A.L., Faille L. The levator auris longus muscle of the mouse: a convenient preparation for studies of short- and long-term presynaptic effects of drugs or toxins. Neurosci. Lett. 1987, 82:83-88.
3. Baggi F., Antozzi C., Toscani C., Cordiglieri C. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?. Arch. Immunol. Ther. Exp. (Warsz) 2012, 60:19-30.
4. Bannister R.A. Bridging the myoplasmic gap: recent developments in skeletal muscle excitation-contraction coupling. J. Muscle Res. Cell Motil. 2007, 28:275-283.
5. Barik A., Lu Y., Sathyamurthy A., Bowman A., Shen C., Li L., Xiong W.C., Mei L. LRP4 is critical for neuromuscular junction maintenance. J. Neurosci. 2014, 34:13892-13905.
6. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul. Disord. 2006, 16:459-467.
7. Bradley S.A., Lyons P.R., Slater C.R. The epitrochleoanconeus muscle (ETA) of the mouse: a useful muscle for the study of motor innervation in vitro. J. Physiol. 1989, 415:3P.
8. Brigant J.L., Mallart A. Presynaptic currents in mouse motor endings. J. Physiol. 1982, 333:619-636.
9. Bruggemann M., Williams G.T., Bindon C.I., Clark M.R., Walker M.R., Jefferis R., Waldmann H., Neuberger M.S. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 1987, 166:1351-1361.
10. Burges J., Vincent A., Molenaar P.C., Newsom-Davis J., Peers C., Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994, 17:1393-1400.
11. Choi B.J., Imlach W.L., Jiao W., Wolfram V., Wu Y., Grbic M., Cela C., Baines R.A., Nitabach M.N., McCabe B.D. Miniature neurotransmission regulates Drosophila synaptic structural maturation. Neuron 2014, 82:618-634.
12. Chroni E., Punga A.R. Neurophysiological characteristics of MuSK antibody positive myasthenia gravis mice: focal denervation and hypersensitivity to acetylcholinesterase inhibitors. J. Neurol. Sci. 2012, 316:150-157.
13. Clarke G.L., Chen J., Nishimune H. Presynaptic active zone density during development and synaptic plasticity. Front. Mol. Neurosci. 2012, 5:12.
14. Cole R.N., Reddel S.W., Gervasio O.L., Phillips W.D. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann. Neurol. 2008, 63:782-789.
15. Colquhoun D., Sakmann B. Fluctuations in the microsecond time range of the current through single acetylcholine receptor ion channels. Nature 1981, 294:464-466.
16. Cronnelly R., Dretchen K.L., Sokoll M.D., Long J.P. Ketamine: myoneural activity and interaction with neuromuscular blocking agents. Eur. J. Pharmacol. 1973, 22:17-22.
17. Cull-Candy S.G., Miledi R., Trautmann A. Acetylcholine-induced channels and transmitter release at human endplates. Nature 1978, 271:74-75.
18. Cull-Candy S.G., Miledi R., Trautmann A., Uchitel O.D. On the release of transmitter at normal, myasthenia gravis and myasthenic syndrome affected human end-plates. J. Physiol. 1980, 299:621-638.
19. Dahlback O., Elmqvist D., Johns T.R., Radner S., Thesleff S. An electrophysiologic study of the neuromuscular junction in myasthenia gravis. J. Physiol. 1961, 156:336-343.
20. Davis G.W. Homeostatic signaling and the stabilization of neural function. Neuron 2013, 80:718-728.
21. Eken T. Spontaneous electromyographic activity in adult rat soleus muscle. J. Neurophysiol. 1998, 80:365-376.
22. Elmqvist D., Johns T.R., Thesleff S. A study of some electrophysiological properties of human intercostal muscle. J. Physiol. 1960, 154:602-607.
23. Elmqvist D., Hofmann W.W., Kugelberg J., Quastel D.M. An electrophysiological investigation of neuromuscular transmission in myasthenia gravis. J. Physiol. 1964, 174:417-434.
24. Engel A.G. Current status of the congenital myasthenic syndromes. Neuromuscul. Disord. 2012, 22:99-111.
25. Engel A.G., Tsujihata M., Lambert E.H., Lindstrom J.M., Lennon V.A. Experimental autoimmune myasthenia gravis: a sequential and quantitative study of the neuromuscular junction ultrastructure and electrophysiologic correlations. J. Neuropathol. Exp. Neurol. 1976, 35:569-587.
26. Engel A.G., Lindstrom J.M., Lambert E.H., Lennon V.A. Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology 1977, 27:307-315.
27. Engel A.G., Ohno K., Milone M., Sine S.M. Congenital myasthenic syndromes. New insights from molecular genetic and patch-clamp studies. Ann. N. Y. Acad. Sci. 1998, 841:140-156.
28. Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., Marino M., Bartoccioni E. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311.
29. Fambrough D.M., Drachman D.B., Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 1973, 182:293-295.
30. Farrugia M.E., Weir A.I., Cleary M., Cooper S., Metcalfe R., Mallik A. Concentric and single fiber needle electrodes yield comparable jitter results in myasthenia gravis. Muscle Nerve 2009, 39:579-585.
31. Frank C.A. Homeostatic plasticity at the Drosophila neuromuscular junction. Neuropharmacology 2014, 78:63-74.
32. Fuchs S., Feferman T., Meidler R., Margalit R., Sicsic C., Brenner T., Laub O., Souroujon M.C. Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction. Ann. N. Y. Acad. Sci. 2008, 1132:244-248.
33. Fuchs S., Aricha R., Reuveni D., Souroujon M.C. Experimental autoimmune myasthenia gravis (EAMG): from immunochemical characterization to therapeutic approaches. J. Autoimmun. 2014, 54:51-59.
34. 2+ overloading. J. Physiol. 2006, 573:35-43.
35. Gasperi C., Melms A., Schoser B., Zhang Y., Meltoranta J., Risson V., Schaeffer L., Schalke B., Kroger S. Anti-agrin autoantibodies in myasthenia gravis. Neurology 2014, 82:1976-1983.
36. Ghazanfari N., Fernandez K.J., Murata Y., Morsch M., Ngo S.T., Reddel S.W., Noakes P.G., Phillips W.D. Muscle specific kinase: organiser of synaptic membrane domains. Int. J. Biochem. Cell Biol. 2011, 43:295-298.
37. Ghazanfari N., Morsch M., Reddel S.W., Liang S.X., Phillips W.D. Muscle-specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction. J. Physiol. 2014, 592:2881-2897.
38. Ghazanfari N., Morsch M., Tse N., Reddel S.W., Phillips W.D. Effects of the beta2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis. PLoS One 2014, 9:e87840.
39. Guptill J.T., Sanders D.B., Evoli A. Anti-musk antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011, 44:36-40.
40. Hennig R., Lomo T. Firing patterns of motor units in normal rats. Nature 1985, 314:164-166.
41. Hesser B.A., Henschel O., Witzemann V. Synapse disassembly and formation of new synapses in postnatal muscle upon conditional inactivation of MuSK. Mol. Cell. Neurosci. 2006, 31:470-480.
42. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann. Neurol. 2011, 69:418-422.
43. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 2001, 7:365-368.
44. Howard J.F. Electrodiagnosis of disorders of neuromuscular transmission. Phys. Med. Rehabil. Clin. N. Am. 2013, 24:169-192.
45. Janssen S.P., Phernambucq M., Martinez-Martinez P., De Baets M.H., Losen M. Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. J. Neuroimmunol. 2008, 201-202:111-120.
46. Jha S., Xu K., Maruta T., Oshima M., Mosier D.R., Atassi M.Z., Hoch W. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J. Neuroimmunol. 2006, 175:107-117.
47. Kaja S., van de Ven R.C., Broos L.A., Veldman H., van Dijk J.G., Verschuuren J.J., Frants R.R., Ferrari M.D., van den Maagdenberg A.M., Plomp J.J. Gene dosage-dependent transmitter release changes at neuromuscular synapses of CACNA1A R192Q knockin mice are non-progressive and do not lead to morphological changes or muscle weakness. Neuroscience 2005, 135:81-95.
48. Kaja S., van de Ven R.C., van Dijk J.G., Verschuuren J.J., Arahata K., Frants R.R., Ferrari M.D., van den Maagdenberg A.M., Plomp J.J. Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacna1a-mutant mouse rolling Nagoya. Eur. J. Neurosci. 2007, 25:2009-2020.
49. Klooster R., Plomp J.J., Huijbers M.G., Niks E.H., Straasheijm K.R., Detmers F.J., Hermans P.W., Sleijpen K., Verrips A., Losen M., Martinez-Martinez P., de Baets M.H., van der Maarel S.M., Verschuuren J.J. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 2012, 135:1081-1101.
50. Koneczny I., Cossins J., Vincent A. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J. Anat. 2014, 224:29-35.
51. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., Beeson D., Willcox N., Vincent A. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
52. Lennon V.A., Lambert E.H. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature 1980, 285:238-240.
53. Lennon V.A., Lindstrom J.M., Seybold M.E. Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 1975, 141:1365-1375.
54. Lin T.S., Cheng K.S. Characterization of the relationship between motor end-plate jitter and the safety factor. Muscle Nerve 1998, 21:628-636.
55. Lindstrom J. Is "seronegative" MG explained by autoantibodies to MuSK?. Neurology 2004, 62:1920-1921.
56. Maselli R.A., Mass D.P., Distad B.J., Richman D.P. Anconeus muscle: a human muscle preparation suitable for in-vitro microelectrode studies. Muscle Nerve 1991, 14:1189-1192.
57. Maselli R.A., Richman D.P., Wollmann R.L. Inflammation at the neuromuscular junction in myasthenia gravis. Neurology 1991, 41:1497-1504.
58. McArdle J.J., Angaut-Petit D., Mallart A., Bournaud R., Faille L., Brigant J.L. Advantages of the triangularis sterni muscle of the mouse for investigations of synaptic phenomena. J. Neurosci. Methods 1981, 4:109-115.
59. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 2004, 55:580-584.
60. McLachlan E.M., Martin A.R. Non-linear summation of end-plate potentials in the frog and mouse. J. Physiol. 1981, 311:307-324.
61. Meriggioli M.N., Sanders D.B. Advances in the diagnosis of neuromuscular junction disorders. Am. J. Phys. Med. Rehabil. 2005, 84:627-638.
62. Meriney S.D., Dittrich M. Organization and function of transmitter release sites at the neuromuscular junction. J. Physiol. 2013, 591:3159-3165.
63. Milone M., Monaco M.L., Evoli A., Servidei S., Tonali P. Ocular myasthenia: diagnostic value of single fibre EMG in the orbicularis oculi muscle. J. Neurol. Neurosurg. Psychiatry 1993, 56:720-721.
64. Milone M., Hutchinson D.O., Engel A.G. Patch-clamp analysis of the properties of acetylcholine receptor channels at the normal human endplate. Muscle Nerve 1994, 17:1364-1369.
65. Molenaar P.C., Polak R.L., Miledi R., Alema S., Vincent A., Newsom-Davis J. Acetylcholine in intercostal muscle from myasthenia gravis patients and in rat diaphragm after blockade of acetylcholine receptors. Prog. Brain Res. 1979, 49:449-458.
66. Molenaar P.C., Oen B.S., Plomp J.J., Van Kempen G.T., Jennekens F.G., Hesselmans L.F. A non-immunogenic myasthenia gravis model and its application in a study of transsynaptic regulation at the neuromuscular junction. Eur. J. Pharmacol. 1991, 196:93-101.
67. Mori S., Kishi M., Kubo S., Akiyoshi T., Yamada S., Miyazaki T., Konishi T., Maruyama N., Shigemoto K. 3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis. J. Neuroimmunol. 2012, 245:75-78.
68. Mori S., Kubo S., Akiyoshi T., Yamada S., Miyazaki T., Hotta H., Desaki J., Kishi M., Konishi T., Nishino Y., Miyazawa A., Maruyama N., Shigemoto K. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am. J. Pathol. 2012, 180:798-810.
69. Morsch M., Reddel S.W., Ghazanfari N., Toyka K.V., Phillips W.D. Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors. Exp. Neurol. 2012, 237:286-295.
70. Morsch M., Reddel S.W., Ghazanfari N., Toyka K.V., Phillips W.D. Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody. J. Physiol. 2013, 591:2747-2762.
71. Nagwaney S., Harlow M.L., Jung J.H., Szule J.A., Ress D., Xu J., Marshall R.M., McMahan U.J. Macromolecular connections of active zone material to docked synaptic vesicles and presynaptic membrane at neuromuscular junctions of mouse. J. Comp. Neurol. 2009, 513:457-468.
72. Newland C.F., Beeson D., Vincent A., Newsom-Davis J. Functional and non-functional isoforms of the human muscle acetylcholine receptor. J. Physiol. 1995, 489(Pt 3):767-778.
73. Niks E.H., Badrising U.A., Verschuuren J.J., van Dijk J.G. Decremental response of the nasalis and hypothenar muscles in myasthenia gravis. Muscle Nerve 2003, 28:236-238.
74. Niks E.H., Kuks J.B., Wokke J.H., Veldman H., Bakker E., Verschuuren J.J., Plomp J.J. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia. Muscle Nerve 2010, 42:283-288.
75. Nishimune H. Active zones of mammalian neuromuscular junctions: formation, density, and aging. Ann. N. Y. Acad. Sci. 2012, 1274:24-32.
76. Nishimune H., Numata T., Chen J., Aoki Y., Wang Y., Starr M.P., Mori Y., Stanford J.A. Active zone protein Bassoon co-localizes with presynaptic calcium channel, modifies channel function, and recovers from aging related loss by exercise. PLoS One 2012, 7:e38029.
77. Oey P.L., Wieneke G.H., Hoogenraad T.U., van Huffelen A.C. Ocular myasthenia gravis: the diagnostic yield of repetitive nerve stimulation and stimulated single fiber EMG of orbicularis oculi muscle and infrared reflection oculography. Muscle Nerve 1993, 16:142-149.
78. Oh S.J., Hatanaka Y., Hemmi S., Young A.M., Scheufele M.L., Nations S.P., Lu L., Claussen G.C., Wolfe G.I. Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis. Muscle Nerve 2006, 33:500-504.
79. Ohno K., Quiram P.A., Milone M., Wang H.L., Harper M.C., Pruitt J.N., Brengman J.M., Pao L., Fischbeck K.H., Crawford T.O., Sine S.M., Engel A.G. Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor epsilon subunit gene: identification and functional characterization of six new mutations. Hum. Mol. Genet. 1997, 6:753-766.
80. Ohta K., Shigemoto K., Fujinami A., Maruyama N., Konishi T., Ohta M. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur. J. Neurol. 2007, 14:1029-1034.
81. Otero-Cruz J.D., Baez-Pagan C.A., Dorna-Perez L., Grajales-Reyes G.E., Ramirez-Ordonez R.T., Luciano C.A., Gomez C.M., Lasalde-Dominicci J.A. Decoding pathogenesis of slow-channel congenital myasthenic syndromes using recombinant expression and mice models. P. R. Health Sci. J. 2010, 29:4-17.
82. Padua L., Stalberg E., LoMonaco M., Evoli A., Batocchi A., Tonali P. SFEMG in ocular myasthenia gravis diagnosis. Clin. Neurophysiol. 2000, 111:1203-1207.
83. Padua L., Caliandro P., Di I.G., Pazzaglia C., Ciaraffa F., Evoli A. Reliability of SFEMG in diagnosing myasthenia gravis: sensitivity and specificity calculated on 100 prospective cases. Clin. Neurophysiol. 2014, 125:1270-1273.
84. Papathanasiou E.S., Zamba-Papanicolaou E. A comparison between disposable and reusable single fiber needle electrodes in relation to stimulated single fiber studies. Clin. Neurophysiol. 2012, 123:1437-1439.
85. Patrick J., Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973, 180:871-872.
86. Pevzner A., Schoser B., Peters K., Cosma N.C., Karakatsani A., Schalke B., Melms A., Kroger S. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J. Neurol. 2012, 259:427-435.
87. Piddlesden S.J., Jiang S., Levin J.L., Vincent A., Morgan B.P. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J. Neuroimmunol. 1996, 71:173-177.
88. Plomp J.J., Van Kempen G.T., Molenaar P.C. Adaptation of quantal content to decreased postsynaptic sensitivity at single endplates in alpha-bungarotoxin-treated rats. J. Physiol. 1992, 458:487-499.
89. Plomp J.J., Van Kempen G.T., Molenaar P.C. The upregulation of acetylcholine release at endplates of alpha-bungarotoxin-treated rats: its dependency on calcium. J. Physiol. 1994, 478(Pt 1):125-136.
90. Plomp J.J., Van Kempen G.T., De Baets M.B., Graus Y.M., Kuks J.B., Molenaar P.C. Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann. Neurol. 1995, 37:627-636.
91. Punga A.R., Flink R., Askmark H., Stalberg E.V. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve 2006, 34:111-115.
92. Punga A.R., Lin S., Oliveri F., Meinen S., Ruegg M.A. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp. Neurol. 2011, 230:207-217.
93. Reddel S.W., Morsch M., Phillips W.D. Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis. Curr. Opin. Neurol. 2014, 27:558-565.
94. Richman D.P., Gomez C.M., Berman P.W., Burres S.A., Fitch F.W., Arnason B.G. Monoclonal anti-acetylcholine receptor antibodies can cause experimental myasthenia. Nature 1980, 286:738-739.
95. Richman D.P., Nishi K., Morell S.W., Chang J.M., Ferns M.J., Wollmann R.L., Maselli R.A., Schnier J., Agius M.A. Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. Arch. Neurol. 2012, 69:453-460.
96. Rodgaard A., Nielsen F.C., Djurup R., Somnier F., Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin. Exp. Immunol. 1987, 67:82-88.
97. Rodriguez Cruz P.M., Palace J., Beeson D. Inherited disorders of the neuromuscular junction: an update. J. Neurol. 2014, 261:2234-2243.
98. Rogozhin A.A., Pang K.K., Bukharaeva E., Young C., Slater C.R. Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A. J. Physiol. 2008, 586:3163-3182.
99. Ruff R.L. Endplate contributions to the safety factor for neuromuscular transmission. Muscle Nerve 2011, 44:854-861.
100. Ruff R.L., Lennon V.A. End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis. Ann. Neurol. 1998, 43:370-379.
101. Sanders D.B., El-Salem K., Massey J.M., McConville J., Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003, 60:1978-1980.
102. Sandrock A.W., Dryer S.E., Rosen K.M., Gozani S.N., Kramer R., Theill L.E., Fischbach G.D. Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo. Science 1997, 276:599-603.
103. Satyamurti S., Drachman D.B., Slone F. Blockade of acetylcholine receptors: a model of myasthenia gravis. Science 1975, 187:955-957.
104. Selcen D., Fukuda T., Shen X.M., Engel A.G. Are MuSK antibodies the primary cause of myasthenic symptoms?. Neurology 2004, 62:1945-1950.
105. Shen C., Lu Y., Zhang B., Figueiredo D., Bean J., Jung J., Wu H., Barik A., Yin D.M., Xiong W.C., Mei L. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J. Clin. Invest. 2013, 123:5190-5202.
106. Shigemoto K., Kubo S., Maruyama N., Hato N., Yamada H., Jie C., Kobayashi N., Mominoki K., Abe Y., Ueda N., Matsuda S. Induction of myasthenia by immunization against muscle-specific kinase. J. Clin. Invest. 2006, 116:1016-1024.
107. Shin H.Y., Park H.J., Lee H.E., Choi Y.C., Kim S.M. Clinical and electrophysiologic responses to acetylcholinesterase inhibitors in MuSK-antibody-positive myasthenia gravis: evidence for cholinergic neuromuscular hyperactivity. J. Clin. Neurol. 2014, 10:119-124.
108. Shiraishi H., Motomura M., Yoshimura T., Fukudome T., Fukuda T., Nakao Y., Tsujihata M., Vincent A., Eguchi K. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann. Neurol. 2005, 57:289-293.
109. Sieb J.P. Myasthenia gravis: an update for the clinician. Clin. Exp. Immunol. 2014, 175:408-418.
110. Sine S.M. End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease. Physiol. Rev. 2012, 92:1189-1234.
111. Slater C.R. Structural determinants of the reliability of synaptic transmission at the vertebrate neuromuscular junction. J. Neurocytol. 2003, 32:505-522.
112. Slater C.R. Structural factors influencing the efficacy of neuromuscular transmission. Ann. N. Y. Acad. Sci. 2008, 1132:1-12.
113. Slater C.R., Lyons P.R., Walls T.J., Fawcett P.R., Young C. Structure and function of neuromuscular junctions in the vastus lateralis of man. A motor point biopsy study of two groups of patients. Brain 1992, 115(Pt 2):451-478.
114. Soltys J., Kusner L.L., Young A., Richmonds C., Hatala D., Gong B., Shanmugavel V., Kaminski H.J. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann. Neurol. 2009, 65:67-75.
115. Sons M.S., Verhage M., Plomp J.J. Role of Munc18-1 in synaptic plasticity at the myasthenic neuromuscular junction. Ann. N. Y. Acad. Sci. 2003, 998:404-406.
116. Sons M.S., Busche N., Strenzke N., Moser T., Ernsberger U., Mooren F.C., Zhang W., Ahmad M., Steffens H., Schomburg E.D., Plomp J.J., Missler M. Alpha-neurexins are required for efficient transmitter release and synaptic homeostasis at the mouse neuromuscular junction. Neuroscience 2006, 138:433-446.
117. Stalberg E.V., Sanders D.B. Jitter recordings with concentric needle electrodes. Muscle Nerve 2009, 40:331-339.
118. Sudhof T.C. Neurotransmitter release: the last millisecond in the life of a synaptic vesicle. Neuron 2013, 80:675-690.
119. Sutton M.A., Ito H.T., Cressy P., Kempf C., Woo J.C., Schuman E.M. Miniature neurotransmission stabilizes synaptic function via tonic suppression of local dendritic protein synthesis. Cell 2006, 125:785-799.
120. Szule J.A., Harlow M.L., Jung J.H., De-Miguel F.F., Marshall R.M., McMahan U.J. Regulation of synaptic vesicle docking by different classes of macromolecules in active zone material. PLoS One 2012, 7:e33333.
121. Tarrab-Hazdai R., Aharonov A., Silman I., Fuchs S., Abramsky O. Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. Nature 1975, 256:128-130.
122. Titulaer M.J., Lang B., Verschuuren J.J. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011, 10:1098-1107.
123. Toyka K.V., Brachman D.B., Pestronk A., Kao I. Myasthenia gravis: passive transfer from man to mouse. Science 1975, 190:397-399.
124. Tsiamalos P., Kordas G., Kokla A., Poulas K., Tzartos S.J. Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece. Eur. J. Neurol. 2009, 16:925-930.
125. Tsujihata M., Hazama R., Ishii N., Ide Y., Takamori M. Ultrastructural localization of acetylcholine receptor at the motor endplate: myasthenia gravis and other neuromuscular diseases. Neurology 1980, 30:1203-1211.
126. Tuzun E., Christadoss P. Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun. Rev. 2013, 12:904-911.
127. Ulusoy C., Kim E., Tuzun E., Huda R., Yilmaz V., Poulas K., Trakas N., Skriapa L., Niarchos A., Strait R.T., Finkelman F.D., Turan S., Zisimopoulou P., Tzartos S., Saruhan-Direskeneli G., Christadoss P. Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice. Clin. Immunol. 2014, 151:155-163.
128. Valls-Canals J., Povedano M., Montero J., Pradas J. Stimulated single-fiber EMG of the frontalis and orbicularis oculi muscles in ocular myasthenia gravis. Muscle Nerve 2003, 28:501-503.
129. Vautrin J., Mambrini J. Synaptic current between neuromuscular junction folds. J. Theor. Biol. 1989, 140:479-498.
130. Verschuuren J.J., Huijbers M.G., Plomp J.J., Niks E.H., Molenaar P.C., Martinez-Martinez P., Gomez A.M., de Baets M.H., Losen M. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun. Rev. 2013, 12:918-923.
131. Viegas S., Jacobson L., Waters P., Cossins J., Jacob S., Leite M.I., Webster R., Vincent A. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp. Neurol. 2012, 234:506-512.
132. Vincent A., Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clin. Exp. Immunol. 1982, 49:257-265.
133. Vincent A., Leite M.I., Farrugia M.E., Jacob S., Viegas S., Shiraishi H., Benveniste O., Morgan B.P., Hilton-Jones D., Newsom-Davis J., Beeson D., Willcox N. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann. N. Y. Acad. Sci. 2008, 1132:84-92.
134. Wang T., Hauswirth A.G., Tong A., Dickman D.K., Davis G.W. Endostatin is a trans-synaptic signal for homeostatic synaptic plasticity. Neuron 2014, 83:616-629.
135. Waud B.E. Decrease in dose requirement of d-tubocurarine by volatile anesthetics. Anesthesiology 1979, 51:298-302.
136. Wood S.J., Slater C.R. Action potential generation in rat slow- and fast-twitch muscles. J. Physiol. 1995, 486(Pt 2):401-410.
137. Wood S.J., Slater C.R. The contribution of postsynaptic folds to the safety factor for neuromuscular transmission in rat fast- and slow-twitch muscles. J. Physiol. 1997, 500(Pt 1):165-176.
138. Wood S.J., Slater C.R. Safety factor at the neuromuscular junction. Prog. Neurobiol. 2001, 64:393-429.
139. Wu B., Goluszko E., Huda R., Tuzun E., Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Curr. Protoc. Immunol. 2013, Unit 15:15.8.1-15.8.26.
140. Xu K., Jha S., Hoch W., Dryer S.E. Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis. Neuroscience 2006, 143:655-659.
141. Zhang B., Tzartos J.S., Belimezi M., Ragheb S., Bealmear B., Lewis R.A., Xiong W.C., Lisak R.P., Tzartos S.J., Mei L. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch. Neurol. 2012, 69:445-451.
142. Zhang B., Shen C., Bealmear B., Ragheb S., Xiong W.C., Lewis R.A., Lisak R.P., Mei L. Autoantibodies to agrin in myasthenia gravis patients. PLoS One 2014, 9:e91816.
143. Zhou Y., Gong B., Lin F., Rother R.P., Medof M.E., Kaminski H.J. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J. Immunol. 2007, 179:8562-8567.
144. Zitman F.M., Todorov B., Jacobs B.C., Verschuuren J.J., Furukawa K., Furukawa K., Willison H.J., Plomp J.J. Neuromuscular synaptic function in mice lacking major subsets of gangliosides. Neuroscience 2008, 156:885-897.